integralife.com - IART Company Value to Revenue Ratio

Competition for clinics with medtech giants in the minimally invasive surgery segment is creating pressure, which the GURU.Markets EV/Revenue chart confirms, with the current metric standing at 1671.10. However, Integra LifeSciences (IART) maintains resilience through its status as a global leader in tissue regeneration and the Codman brand, while the deep integration of its tools into operating rooms minimizes switching risks.
IART (Integra): analytical breakdowns and indicator data

The EV/Sales multiple determines the enterprise value of a business, including net debt, per unit of generated revenue. By analyzing the enterprise value-to-revenue trend, an investor assesses the capitalization efficiency of operating flows without the influence of financing structure. A decline in this metric may signal either an undervaluation or a risk of margin compression. For Integra LifeSciences (IART), a high valuation is justified by exceptional pricing power. Its monopoly position in the critical neurosurgical membranes segment makes revenue resilient to market fluctuations.